Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)

New Drug Application filing anticipated based on positive data from interim analysis 21 June 2022 -- Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials